RT Journal Article
T1 Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections.
A1 Guisado-Gil, Ana Belen
A1 Infante-Domínguez, Carmen
A1 Peñalva, Germán
A1 Praena, Julia
A1 Roca, Cristina
A1 Navarro-Amuedo, María Dolores
A1 Aguilar-Guisado, Manuela
A1 Espinosa-Aguilera, Nuria
A1 Poyato-Borrego, Manuel
A1 Romero-Rodríguez, Nieves
A1 Aldabó, Teresa
A1 Salto-Alejandre, Sonsoles
A1 Ruiz-Pérez de Pipaón, Maite
A1 Lepe, José Antonio
A1 Martín-Gutiérrez, Guillermo
A1 Gil-Navarro, María Victoria
A1 Molina, José
A1 Pachón, Jerónimo
A1 Cisneros, José Miguel
A1 On Behalf Of The Prioam Team, 
K1 COVID-19
K1 anti-infective agents
K1 antimicrobial stewardship
K1 bacteremia
K1 candidemia
AB During the COVID-19 pandemic, the implementation of antimicrobial stewardship strategies has been recommended. This study aimed to assess the impact of the COVID-19 pandemic in a tertiary care Spanish hospital with an active ongoing antimicrobial stewardship programme (ASP). For a 20-week period, we weekly assessed antimicrobial consumption, incidence density, and crude death rate per 1000 occupied bed days of candidemia and multidrug-resistant (MDR) bacterial bloodstream infections (BSI). We conducted a segmented regression analysis of time series. Antimicrobial consumption increased +3.5% per week (p = 0.016) for six weeks after the national lockdown, followed by a sustained weekly reduction of -6.4% (p = 0.001). The global trend for the whole period was stable. The frequency of empirical treatment of patients with COVID-19 was 33.7%. No change in the global trend of incidence of hospital-acquired candidemia and MDR bacterial BSI was observed (+0.5% weekly; p = 0.816), nor differences in 14 and 30-day crude death rates (p = 0.653 and p = 0.732, respectively). Our work provides quantitative data about the pandemic effect on antimicrobial consumption and clinical outcomes in a centre with an active ongoing institutional and education-based ASP. However, assessing the long-term impact of the COVID-19 pandemic on antimicrobial resistance is required.
SN 2079-6382
YR 2020
FD 2020-11-17
LK https://hdl.handle.net/10668/28034
UL https://hdl.handle.net/10668/28034
LA en
DS RISalud
RD Apr 12, 2025